FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068887075> ?p ?o ?g. }

• W2068887075 endingPage "655" @default.
• W2068887075 startingPage "648" @default.
• W2068887075 abstract "1. The desensitizing acetylcholine (ACh) response of bovine chromaffin cells maintained in culture was examined using rapid agonist applications (of 2 s duration) which imposed nominal drug concentrations within 50 ms. This study was aimed, firstly, at identifying which of the alpha 3, alpha 4 and alpha 7 subunits known to be present in these cells is predominant in the ACh-evoked response and secondly, on the effects on these neuronal nicotinic ACh receptors (AChR) of cyclothiazide (CT), an agent acting as a modulator of a gating desensitization site on other ligand-gated channels. 2. Locally applied 100 microM ACh evoked peak currents (IACh) of -1.5 +/- 0.1 nA (n = 83) at a holding potential of -60 mV. The ACh dose-response curve yielded an estimated EC50 of 60 microM. This current was not sustained but desensitized during the application period; it displayed strong inward rectification, but desensitized equally whether the evoked current was inward or outward going. The latter observation excludes alpha 4 as a major contributor to the recorded current. Because the response was almost insensitive to a 1 microM alpha-bungarotoxin pretreatment (IACh = -1.2 +/- 0.1 nA; n = 6), and because 1, 1-dimethyl-4-phenylpiperazinium (DMPP) works as a potent agonist (peak current = -1.9 nA, n = 2 for 100 microM DMPP), the alpha 7 subunit is also a minor contributor to the response. Taken together, these observations suggest a dominant alpha 3 type of response. 3. Triple exponential fits were used to describe the characteristics of the ACh-evoked currents; one component to fit the rising phase, with 2 components to describe the decay phase. The decay times were 100 ms and 4 s for the fast and slow components respectively. The rate of the slow decay component increased systematically with recording time, approximately doubling from its initial value within 20-40 min. Furthermore there was a gradual rundown of the response, seen first as a loss of the late component of the current, measured at 2 s, with the peak current amplitude decreasing later in the recording.4. CT, when coapplied with ACh, produced a dose-dependent inhibition of the ACh-evoked peak current. The effect showed little voltage-dependency with 100 microM CT producing 46 +/- 5% (s.d.; n = 3)and 47 +/- 8% (s.d.; n = 7) inhibition at -100 and -60 mV respectively. At + 60 mV, inhibition was estimated to be 26 +/- 7% (s.d.; n = 3).5. After pre-exposure of the cells to CT by bath application, 10 and 30 microM CT produced poorly reversible 20 +/- 9% (n = 7) and 42 +/- 5% (n = 4) inhibitions of the peak current respectively. There were no discernible effects on the fitted decay constants at any CT concentration tested, although an increased inhibitory effect of CT was observed at higher concentrations (100 microM) on the amplitude of the late component measured at 2 s.6. Similar effects were observed in conditions chosen to isolate the alpha 3 type of receptor: namely when using DMPP as an agonist, or after a-bungarotoxin pretreatment.7. The 2,3-benzodiazepine, GYKI 53655, is known to antagonize the action of CT on AMPA receptors.Coapplication of 50 microM GYKI 53655 with ACh (100 microM) produced a 29 +/- 4% inhibition of the peak ACh-evoked current and 44 +/- 6% inhibition of its amplitude at 2 s (n = 4). This response was fully reversible. Brief applications of both CT (100 microM) and GYKI 53655 (50 microM) with ACh via the microperfusion system produced a fully reversible inhibition that was not significantly different from the values obtained with either CT or GYKI 53655 alone, with 37 +/- 6% inhibition of peak and 61 +/- 9%inhibition of the amplitude at 2 s (n = 3).8. The results obtained suggest that the CT effect is to impede recovery from a slow desensitization,with a more pronounced effect with longer CT applications. Globally, CT favours the 'rundown state' of the neuronal nicotinic AChR." @default.
• W2068887075 created "2016-06-24" @default.
• W2068887075 creator A5003416284 @default.
• W2068887075 creator A5085251382 @default.
• W2068887075 date "1995-02-01" @default.
• W2068887075 modified "2023-10-07" @default.
• W2068887075 title "Inhibition by cyclothiazide of neuronal nicotinic responses in bovine chromaffin cells" @default.
• W2068887075 cites W1516371256 @default.
• W2068887075 cites W1567416559 @default.
• W2068887075 cites W1608817464 @default.
• W2068887075 cites W1636225847 @default.
• W2068887075 cites W1876613592 @default.
• W2068887075 cites W1900806927 @default.
• W2068887075 cites W1951847360 @default.
• W2068887075 cites W1971009901 @default.
• W2068887075 cites W1978224954 @default.
• W2068887075 cites W1992064771 @default.
• W2068887075 cites W1994279940 @default.
• W2068887075 cites W2006110086 @default.
• W2068887075 cites W2011390733 @default.
• W2068887075 cites W2019678745 @default.
• W2068887075 cites W2026431577 @default.
• W2068887075 cites W2035499517 @default.
• W2068887075 cites W2041399253 @default.
• W2068887075 cites W2045637156 @default.
• W2068887075 cites W2053656727 @default.
• W2068887075 cites W2055320926 @default.
• W2068887075 cites W2055584490 @default.
• W2068887075 cites W2057745157 @default.
• W2068887075 cites W2062662553 @default.
• W2068887075 cites W2062790537 @default.
• W2068887075 cites W2063792561 @default.
• W2068887075 cites W2065808106 @default.
• W2068887075 cites W2069258575 @default.
• W2068887075 cites W2070295245 @default.
• W2068887075 cites W2083836609 @default.
• W2068887075 cites W2088880312 @default.
• W2068887075 cites W2110103662 @default.
• W2068887075 cites W2137760362 @default.
• W2068887075 cites W2159695505 @default.
• W2068887075 cites W2167825748 @default.
• W2068887075 doi "https://doi.org/10.1111/j.1476-5381.1995.tb17188.x" @default.
• W2068887075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1510031" @default.
• W2068887075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7735691" @default.
• W2068887075 hasPublicationYear "1995" @default.
• W2068887075 type Work @default.
• W2068887075 sameAs 2068887075 @default.
• W2068887075 citedByCount "22" @default.
• W2068887075 countsByYear W20688870752012 @default.
• W2068887075 countsByYear W20688870752017 @default.
• W2068887075 countsByYear W20688870752018 @default.
• W2068887075 countsByYear W20688870752019 @default.
• W2068887075 crossrefType "journal-article" @default.
• W2068887075 hasAuthorship W2068887075A5003416284 @default.
• W2068887075 hasAuthorship W2068887075A5085251382 @default.
• W2068887075 hasBestOaLocation W20688870751 @default.
• W2068887075 hasConcept C12554922 @default.
• W2068887075 hasConcept C126322002 @default.
• W2068887075 hasConcept C134018914 @default.
• W2068887075 hasConcept C147944092 @default.
• W2068887075 hasConcept C159110408 @default.
• W2068887075 hasConcept C170493617 @default.
• W2068887075 hasConcept C185592680 @default.
• W2068887075 hasConcept C188987157 @default.
• W2068887075 hasConcept C2775894120 @default.
• W2068887075 hasConcept C2775910092 @default.
• W2068887075 hasConcept C2775944032 @default.
• W2068887075 hasConcept C2777597313 @default.
• W2068887075 hasConcept C2778071365 @default.
• W2068887075 hasConcept C2778938600 @default.
• W2068887075 hasConcept C2780910648 @default.
• W2068887075 hasConcept C2909754679 @default.
• W2068887075 hasConcept C49453240 @default.
• W2068887075 hasConcept C55493867 @default.
• W2068887075 hasConcept C64943373 @default.
• W2068887075 hasConcept C71924100 @default.
• W2068887075 hasConcept C80161118 @default.
• W2068887075 hasConcept C86803240 @default.
• W2068887075 hasConceptScore W2068887075C12554922 @default.
• W2068887075 hasConceptScore W2068887075C126322002 @default.
• W2068887075 hasConceptScore W2068887075C134018914 @default.
• W2068887075 hasConceptScore W2068887075C147944092 @default.
• W2068887075 hasConceptScore W2068887075C159110408 @default.
• W2068887075 hasConceptScore W2068887075C170493617 @default.
• W2068887075 hasConceptScore W2068887075C185592680 @default.
• W2068887075 hasConceptScore W2068887075C188987157 @default.
• W2068887075 hasConceptScore W2068887075C2775894120 @default.
• W2068887075 hasConceptScore W2068887075C2775910092 @default.
• W2068887075 hasConceptScore W2068887075C2775944032 @default.
• W2068887075 hasConceptScore W2068887075C2777597313 @default.
• W2068887075 hasConceptScore W2068887075C2778071365 @default.
• W2068887075 hasConceptScore W2068887075C2778938600 @default.
• W2068887075 hasConceptScore W2068887075C2780910648 @default.
• W2068887075 hasConceptScore W2068887075C2909754679 @default.
• W2068887075 hasConceptScore W2068887075C49453240 @default.
• W2068887075 hasConceptScore W2068887075C55493867 @default.
• W2068887075 hasConceptScore W2068887075C64943373 @default.
• W2068887075 hasConceptScore W2068887075C71924100 @default.

• next